Biological Omics Analysis of Tumor Mutation Burden Combined with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma
暂无分享,去创建一个
Guang Li | Jin Huang | Y. Zhuang | Chang Liu | Zhuang Yuan
[1] Jia Lv,et al. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer , 2020, Bioscience reports.
[2] A. Green,et al. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. , 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[3] E. Yakirevich,et al. Tumor mutational burden and immune signatures interplay in renal cell carcinoma , 2020, Annals of translational medicine.
[4] Michael S. Goldberg,et al. Improving cancer immunotherapy through nanotechnology , 2019, Nature Reviews Cancer.
[5] Jianliu Wang,et al. The Role of Metabolic Syndrome in Endometrial Cancer: A Review , 2019, Front. Oncol..
[6] A. Haque,et al. Development of circulating CD4+ T‐cell memory , 2019, Immunology and cell biology.
[7] S. Khakoo,et al. Immunotherapy for hepatocellular carcinoma: Current and future , 2019, World journal of gastroenterology.
[8] C. Marchetti,et al. Immune check-point in endometrial cancer , 2019, International Journal of Clinical Oncology.
[9] T A Chan,et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Puja Sharma,et al. Receptor-Targeted Glial Brain Tumor Therapies , 2018, International journal of molecular sciences.
[11] Yong Teng,et al. Making way for suppressing the FGF19/FGFR4 axis in cancer. , 2018, Future medicinal chemistry.
[12] B. Taylor,et al. Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer , 2018, Clinical Cancer Research.
[13] Guangxu Jin,et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer , 2018, Oncoimmunology.
[14] Arun Ahuja,et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer , 2018, Cancer cell.
[15] E. Jaffee,et al. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.
[16] R. Puri,et al. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme , 2017, Journal of Neuro-Oncology.
[17] Russell Bonneville,et al. Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.
[18] K. Schmitz,et al. Obesity and Endometrial Cancer: A Lack of Knowledge but Opportunity for Intervention , 2017, Nutrition and cancer.
[19] P. Stephens,et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.
[20] Ping-Chih Ho,et al. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy. , 2017, Trends in cancer.
[21] R. Madan,et al. Immunotherapy of Prostate Cancer: Facts and Hopes , 2017, Clinical Cancer Research.
[22] H. Rugo,et al. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Schadendorf,et al. Immunotherapy in melanoma: Recent advances and future directions. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[24] R. Herbst,et al. Immunotherapy in Lung Cancer. , 2017, Hematology/oncology clinics of North America.
[25] A. Oza,et al. Treatment strategies for endometrial cancer: current practice and perspective , 2017, Current opinion in obstetrics & gynecology.
[26] S. Devadas,et al. Regulators of Tfh Cell Differentiation , 2016, Front. Immunol..
[27] R. Motzer,et al. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma , 2016, Nature Reviews Urology.
[28] E. Nowakowska-Zajdel,et al. Epigenetic silencing of endothelin-3 in colorectal cancer , 2016, International journal of immunopathology and pharmacology.
[29] Michael M. Braun,et al. Diagnosis and Management of Endometrial Cancer. , 2016, American family physician.
[30] Lauren L. Ritterhouse,et al. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. , 2015, JAMA oncology.
[31] M. Raes,et al. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide , 2015, BMC Cancer.
[32] S. Kondo,et al. Clinical Development of Immune Checkpoint Inhibitors , 2015, BioMed research international.
[33] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[34] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[35] F. Amant,et al. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy , 2014, Cancer Immunology, Immunotherapy.
[36] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[37] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[38] Hassan Ashktorab,et al. Epigenetic inactivation of endothelin‐2 and endothelin‐3 in colon cancer , 2013, International journal of cancer.
[39] J. Casal,et al. High expression of IL-13 receptor α2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. , 2012, Cancer research.
[40] H. Kitchener,et al. Adjuvant radiotherapy for stage I endometrial cancer. , 2012, The Cochrane database of systematic reviews.
[41] M. Jenkins,et al. Origins of CD4+ effector and central memory T cells , 2011, Nature Immunology.
[42] A. N. Meyer,et al. The Receptor Tyrosine Kinase FGFR4 Negatively Regulates NF-kappaB Signaling , 2010, PloS one.
[43] M. Esteller,et al. Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer , 2009, Breast Cancer Research.
[44] Y. Liu,et al. Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells. , 2007, Human pathology.
[45] R W Raven,et al. The british association of surgical oncology , 1973, Annals of the Royal College of Surgeons of England.
[46] L. Liau,et al. Cell-Based Immunotherapy of Gliomas. , 2018, Progress in neurological surgery.
[47] M. Brewer,et al. Endometrial Cancer: Is This a New Disease? , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[48] I. Simera,et al. Adjuvant radiotherapy for stage I endometrial cancer. , 2007, The Cochrane database of systematic reviews.
[49] Patrick Neven,et al. Endometrial cancer. , 2005, Lancet.